Highly Stereoselective Hydrogenations-As Key-Steps in the Total Synthesis of Statins

被引：16

作者：

Andrushko, Natalia ^{[1
]}

Andrushko, Vasyl ^{[1
]}

Tararov, Vitali ^{[1
]}

Korostylev, Andrei ^{[1
]}

Koenig, Gerd ^{[2
]}

Boerner, Armin ^{[1
,3
]}

机构：

[1] Univ Rostock eV, Leibniz Inst Katalyse, D-18059 Rostock, Germany

[2] Ratiopharm GmbH, D-89070 Ulm, Germany

[3] Univ Rostock, Inst Chem, D-18059 Rostock, Germany

来源：

CHIRALITY | 2010年 / 22卷 / 05期

关键词：

drug synthesis; atorvastatin; rosuvastatin; asymmetric hydrogenation; enantioselectivity; stereoselectivity; statins; asymmetric catalysis; TISSUE-SELECTIVE INHIBITOR; CARDIOVASCULAR-DISEASE; ATORVASTATIN; ROSUVASTATIN; INTERMEDIATE; CHOLESTEROL; 6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE; HYPERLIPIDEMIA; SIMVASTATIN; PRAVASTATIN;

D O I：

10.1002/chir.20782

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long-term benefits. They are administered as diastereo- and enantiomerically pure compounds. We summarize here two new approaches for the total synthesis of the most important representatives, atorvastatin, and rosuvastatin, based on highly stereoselective hydrogenations as key-steps. Chirality 22:534-541,2010. (C) 2009 Wiley-Liss, Inc.

引用

页码：534 / 541

页数：8

共 41 条

[1] A new approach to the total synthesis of rosuvastatin [J].

Andrushko, Natalia ;

Andrushko, Vasyl ;

Koenig, Gerd ;

Spannenberg, Anke ;

Boerner, Armin .

EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2008, 2008 (05) :847-853

[2] Highly enantioselective catalytic hydrogenation of a 5-amino-3,5-dioxopentanoic ester [J].

Andrushko, Vasyl ;

Andrushko, Natalia ;

Koenig, Gerd ;

Boerner, Armin .

TETRAHEDRON LETTERS, 2008, 49 (33) :4836-4839

[3]

Balanov A., 2007, US Patent Appl, Patent No. [2007167625, US 2007167625 A1]

[4] THE CONVERGENT SYNTHESIS OF CI-981, AN OPTICALLY-ACTIVE, HIGHLY POTENT, TISSUE SELECTIVE INHIBITOR OF HMG-COA REDUCTASE [J].

BAUMANN, KL ;

BUTLER, DE ;

DEERING, CF ;

MENNEN, KE ;

MILLAR, A ;

NANNINGA, TN ;

PALMER, CW ;

ROTH, BD .

TETRAHEDRON LETTERS, 1992, 33 (17) :2283-2284

[5] C-ACYLATION UNDER VIRTUALLY NEUTRAL CONDITIONS [J].

BROOKS, DW ;

LU, LDL ;

MASAMUNE, S .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1979, 18 (01) :72-74

[6] THE SYNTHESIS OF (4R-CIS)-1,1-DIMETHYLETHYL 6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE, A KEY INTERMEDIATE FOR THE PREPARATION OF CI-981, A HIGHLY POTENT, TISSUE SELECTIVE INHIBITOR OF HMG-COA REDUCTASE [J].

BROWER, PL ;

BUTLER, DE ;

DEERING, CF ;

LE, TV ;

MILLAR, A ;

NANNINGA, TN ;

ROTH, BD .

TETRAHEDRON LETTERS, 1992, 33 (17) :2279-2282

[7]

Casar Z., 2008, Eur. Pat. Appl., Patent No. [EP 1978020 A1, 1978020]

[8] Pharmacogenetic study of statin therapy and cholesterol reduction [J].

Chasman, DI ;

Posada, D ;

Subrahmanyan, L ;

Cook, NR ;

Stanton, VP ;

Ridker, PM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (23) :2821-2827

[9] Atorvastatin - A review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus [J].

Croom, KF ;

Plosker, GL .

DRUGS, 2005, 65 (01) :137-152

[10] Rosuvastatin for the treatment of hypercholesterolemia [J].

Culhane, NS ;

Lettieri, SL ;

Skae, JR .

PHARMACOTHERAPY, 2005, 25 (07) :990-1000

← 1 2 3 4 5 →